Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \>=40 years of age~* diagnosed COPD with symptoms \>= 2 years~* pre-bronchodilatory FEV1 \<=50% of PN~Exclusion Criteria:~* Current respiratory tract disorder other than COPD~* history of asthma or rhinitis~* significant or unstable cardiovascular disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symbicort then Formoterol then Placebo (Type: EXPERIMENTAL): Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
- Formoterol then Symbicort then Placebo (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
- Placebo then Formoterol then Symbicort (Type: PLACEBO_COMPARATOR): Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).